Keeping Canadians with rare disorders from getting the drugs they need to stay alive

The Canadian government, acting through Health Canada’s Common Drug Review (CDR), is keeping Canadians with rare disorders from getting the drugs they need to stay alive, according to Durhane Wong-Rieger, president of the Canadian Organization for Rare Disorders (CORD). Because each disease impacts so few individuals, the drugs needed to treat these small populations—the so-called orphan drugs—the CDR does not generally recommend for government drug plans, despite the drugs having received regulatory approval from Health Canada itself.

  • Dr. Durhane Wong-Rieger, PhD, Psychologist, president of the Canadian Organization for Rare Disorders (CORD), president and CEO of the Anemia Institute of Research and Education, past president of the Canadian Hemophilia Society, past-director of Canadian Blood Services, executive member of National Blood Safety Council, consumer advocate for blood safety and alternatives.

Leave a Reply